期刊
CURRENT OPINION IN IMMUNOLOGY
卷 35, 期 -, 页码 73-79出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2015.06.007
关键词
-
类别
资金
- National Institute of Health (NIAID) [AI094444, AI118182]
- National Institute of Health (NIBIB) [EB009701]
- National Institute of Health (NIAMS) [AR066244]
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI118182, R21AI094444] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R21AR066244] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB009701] Funding Source: NIH RePORTER
Successful immunotherapies must be designed to elicit targeted immune responses having a specifiable phenotype across many dimensions, including the phenotypes of T cells, B cells, antigen-presenting cells, and others. For synthetic or subunit vaccines, stimulation of strong enough immune responses usually requires adjuvants, which can cause local inflammation and complicate the targeting of such phenotypes. Supramolecular materials provide routes for reducing or eliminating supplemental adjuvants. Owing to their compositional controllability, supramolecular assemblies show promise for fine-tuning immune responses by adjusting combinations of material attributes including epitope content, multivalency, size, dose, and small quantities of specific adjuvants. Here we focus on supramolecular vaccines incorporating multiple epitopes in precise ratios, with an emphasis on peptides that form high-aspect ratio (i.e. fibrillar) structures.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据